Across TCGA pan-cancer cohorts, CFAP54 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CFAP54 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CFAP54 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CFAP54 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.
LIHC, UCEC, and OV are the cancer types where CFAP54 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.